Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.52 · Revenue $454000.00 · 5 analysts
Est. EPS $-1.50 · Revenue $577286.00 · 5 analysts
Est. EPS $-0.27 · Revenue $545100.00 · 2 analysts
Est. EPS $-0.26 · Revenue $1.76M · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $33.5M | +1169.2% | -20.0% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-52.7M | +13.6% | -14.8% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +99.4% | +7.8% | +337.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -154.7% | +93.7% | -26.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -157.4% | +93.2% | -43.5% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-49.5M | +2.7% | +12.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -147.7% | +92.3% | -9.5% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 25.2% | -49.8% | +264.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.45x | +51.1% | +17.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $114.9M | +50.8% | +14.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.11 vs -1.74 | +36.3% | -0.38 vs -0.27 | -41.2% |
| Revenue Surprise | $33.5M vs $3.5M | +865.4% | $88000 vs $545100 | -83.9% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Sherman Darren | director, officer: See Remarks | Common Stock, par value $0.0001 per share ("Common Stock") | D | 15,000 | $4.94 |
| Aug 26, 2026 | Taylor Andrew Lawrence | officer: Chief Financial Officer | Common Stock, par value $0.0001 per share | D | 3,076 | $5.26 |
| Aug 26, 2026 | Sherman Darren | director, officer: See Remarks | Common Stock, par value $0.0001 per share ("Common Stock") | D | 4,925 | $5.26 |
| Aug 26, 2026 | Sherman Darren | director, officer: See Remarks | Common Stock | A | 2,000 | $5.33 |
| Aug 26, 2026 | Aiello Joshua | officer: Principal Accounting Officer | Common Stock, par value $0.0001 per share | D | 203 | $5.26 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
David Hochman | Founder, Chairman of the Board of Directors & Chief Executive Officer | USD 1,179,259 | Male | 1975 | Active |
Darren R. Sherman | Founder, President, Chief Operating Officer & Director | USD 1,041,640 | Male | 1971 | Active |
Andrew Lawrence Taylor | Chief Financial Officer | USD 766,677 | Male | 1971 | Active |
Yuval Hay Mika D.Sc | GM & Chief Technology Officer of Bioelectronic Therapies | — | — | 1959 | Active |
Bob Laughner | Senior Vice President of Regulatory & Quality | — | Male | — | Active |
William Reed Little | Executive Vice President of Corporate Development & Strategy | — | Male | 1971 | Active |
Avraham Matityahu Fischer | Senior Vice President of Medical Affairs & Innovation | — | — | 1956 | Active |
Hans-Peter Stoll | Senior Vice President & Medical Director | — | — | — | Active |
Juan Lorenzo | Senior Vice President of Product Development | — | Male | — | Active |
Lisa Daniels | Vice President of Human Resources | — | Female | — | Active |
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago.
Affinity Asset Advisors LLC lessened its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) by 29.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 402,550 shares of the company's stock after selling 170,254 shares during the quarter. Affinity Asset Advisors
Orchestra BioMed is approaching pivotal trial readouts for AVIM Therapy and Virtue SAB, both with strong success potential. OBIO operates as an innovation and clinical development platform for medical devices, relying on Medtronic and Terumo for commercialization. Medtronic and Terumo have invested a combined $146 million, with OBIO's $220 million valuation reflecting a modest premium to strategic funding and with significant potential upside as catalysts approach.
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026.
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 85,500 shares of the Company's common stock to five newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options granted to each new employee will vest over a four-year period.
